Drug Profile
PSC 100
Alternative Names: HPDSC; Human placenta-derived stem cells; Placental-derived stem cell therapy - Celularity; PSC-100; UCB + HPDSC; UCB and HPDSCLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Celgene Corporation; Human Longevity
- Developer Celgene Corporation; Celularity; Human Longevity; New York Medical College
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epidermolysis bullosa; Haematological disorders; Haematological malignancies; Inflammation; Sarcopenia
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Epidermolysis-bullosa in USA
- 28 Mar 2022 No recent reports of development identified for preclinical development in Inflammation in USA (IV)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Haematological-disorders in USA (IV)